ArticleJAAD international2025

NRAS tumor mutations are associated with reduced odds of dermatologic adverse events in patients with metastatic melanoma receiving immune checkpoint inhibitors.

Michael S Chang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.